COGT
Cogent Biosciences
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Cogent Biosciences receives FDA acceptance and priority review for bezuclastinib NDA in GIST patientsMay 28, 2026
- The FDA accepted Cogent Biosciences’ NDA for bezuclastinib to treat non-advanced systemic mastocytosisMar 16, 2026
- Cogent Biosciences received Breakthrough Therapy designation for bezuclastinib plus sunitinib in GISTJan 27, 2026
- Cogent Biosciences submits NDA for bezuclastinib in nonadvanced systemic mastocytosisDec 30, 2025
- Cogent Biosciences reports positive results from Bezuclastinib PEAK Phase 3 trial in gastrointestinal stromal tumorsNov 10, 2025